Literature DB >> 16837672

In vitro and in vivo imaging studies of a new endohedral metallofullerene nanoparticle.

Panos P Fatouros1, Frank D Corwin, Zhi-Jian Chen, William C Broaddus, James L Tatum, Birgit Kettenmann, Zhongxin Ge, Harry W Gibson, Jennifer L Russ, Anthony P Leonard, James C Duchamp, Harry C Dorn.   

Abstract

PURPOSE: To evaluate the effectiveness of a functionalized trimetallic nitride endohedral metallofullerene nanoparticle as a magnetic resonance (MR) imaging proton relaxation agent and to follow its distribution for in vitro agarose gel infusions and in vivo infusions in rat brain.
MATERIALS AND METHODS: The animal study was approved by the animal care and use committee. Gd(3)N@C(80) was functionalized with poly(ethylene glycol) units, and the carbon cage was hydroxylated to provide improved water solubility and biodistribution. Relaxation rate measurements (R1 = 1/T1 and R2 = 1/T2) of water solutions of this contrast agent were conducted at 0.35-, 2.4-, and 9.4-T MR imaging. Images of contrast agent distributions were produced following infusions in six agarose gel samples at 2.4 T and from direct brain infusions into normal and tumor-bearing rat brain at 2.4 T. The relaxivity of a control functionalized lutetium agent, Lu(3)N@C(80), was also determined.
RESULTS: Water hydrogen MR imaging relaxivity (r1) for this metallofullerene nanoparticle was markedly higher than that for commercial agents (eg, gadodiamide); r1 values of 102, 143, and 32 L . mmol(-1) . sec(-1) were measured at 0.35, 2.4, and 9.4 T, respectively. In studies of in vitro agarose gel infusion, the use of functionalized Gd(3)N@C(80) at concentrations an order of magnitude lower resulted in equivalent visualization in comparison with commercial agents. Comparable contrast enhancement was obtained with direct infusions of 0.013 mmol/L of Gd(3)N@C(80) and 0.50 mmol/L of gadodiamide in live normal rat brain. Elapsed-time studies demonstrated lower diffusion rates for Gd(3)N@C(80) relative to gadodiamide in live normal rat brain tissue. Functionalized metallofullerenes directly infused into a tumor-bearing brain provided an improved tumor delineation in comparison with the intravenously injected conventional Gd(3+) chelate. A control lutetium functionalized Lu(3)N@C(80) nanoparticle exhibited very low MR imaging relaxivity.
CONCLUSION: The new functionalized trimetallic nitride endohedral metallofullerene species Gd(3)N@C(80)[DiPEG5000(OH)(x)] is an effective proton relaxation agent, as demonstrated with in vitro relaxivity and MR imaging studies, in infusion experiments with agarose gel and in vivo rat brain studies simulating clinical conditions of direct intraparenchymal drug delivery for the treatment of brain tumors. (c) RSNA, 2006.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16837672     DOI: 10.1148/radiol.2403051341

Source DB:  PubMed          Journal:  Radiology        ISSN: 0033-8419            Impact factor:   11.105


  37 in total

1.  Safety and Efficacy of A High Performance Graphene-Based Magnetic Resonance Imaging Contrast Agent for Renal Abnormalities.

Authors:  Shruti Kanakia; Jimmy Toussaint; Praveen Kukarni; Stephen Lee; Sayan Mullick Chowdhury; Slah Khan; Sandeep K Mallipattu; Kenneth R Shroyer; William Moore; Balaji Sitharaman
Journal:  Graphene Technol       Date:  2016-08-03

Review 2.  Detecting and treating cancer with nanotechnology.

Authors:  Keith B Hartman; Lon J Wilson; Michael G Rosenblum
Journal:  Mol Diagn Ther       Date:  2008       Impact factor: 4.074

3.  Metallofullerene-based nanoplatform for brain tumor brachytherapy and longitudinal imaging in a murine orthotopic xenograft model.

Authors:  Michael D Shultz; John D Wilson; Christine E Fuller; Jianyuan Zhang; Harry C Dorn; Panos P Fatouros
Journal:  Radiology       Date:  2011-08-03       Impact factor: 11.105

Review 4.  Enabling individualized therapy through nanotechnology.

Authors:  Jason H Sakamoto; Anne L van de Ven; Biana Godin; Elvin Blanco; Rita E Serda; Alessandro Grattoni; Arturas Ziemys; Ali Bouamrani; Tony Hu; Shivakumar I Ranganathan; Enrica De Rosa; Jonathan O Martinez; Christine A Smid; Rachel M Buchanan; Sei-Young Lee; Srimeenakshi Srinivasan; Matthew Landry; Anne Meyn; Ennio Tasciotti; Xuewu Liu; Paolo Decuzzi; Mauro Ferrari
Journal:  Pharmacol Res       Date:  2010-01-05       Impact factor: 7.658

Review 5.  Macromolecules, dendrimers, and nanomaterials in magnetic resonance imaging: the interplay between size, function, and pharmacokinetics.

Authors:  Aaron Joseph L Villaraza; Ambika Bumb; Martin W Brechbiel
Journal:  Chem Rev       Date:  2010-05-12       Impact factor: 60.622

Review 6.  Molecular imaging with nanoparticles: giant roles for dwarf actors.

Authors:  Paul Debbage; Werner Jaschke
Journal:  Histochem Cell Biol       Date:  2008-09-30       Impact factor: 4.304

7.  Trimetallic Nitride Endohedral Fullerenes Carboxyl-Gd3N@C80: A New Theranostic Agent for Combating Oxidative Stress and Resolving Inflammation.

Authors:  Tinghui Li; Li Xiao; Jiezuan Yang; Mengmeng Ding; Zhiguo Zhou; Leslie LaConte; Li Jin; Harry C Dorn; Xudong Li
Journal:  ACS Appl Mater Interfaces       Date:  2017-05-19       Impact factor: 9.229

Review 8.  Clearance properties of nano-sized particles and molecules as imaging agents: considerations and caveats.

Authors:  Michelle Longmire; Peter L Choyke; Hisataka Kobayashi
Journal:  Nanomedicine (Lond)       Date:  2008-10       Impact factor: 5.307

9.  Facile preparation of a new gadofullerene-based magnetic resonance imaging contrast agent with high 1H relaxivity.

Authors:  Chunying Shu; Frank D Corwin; Jianfei Zhang; Zhijian Chen; Jonathan E Reid; Minghao Sun; Wei Xu; Jae Hyun Sim; Chunru Wang; Panos P Fatouros; Alan R Esker; Harry W Gibson; Harry C Dorn
Journal:  Bioconjug Chem       Date:  2009-06       Impact factor: 4.774

10.  Water-soluble fullerene (C60) derivatives as nonviral gene-delivery vectors.

Authors:  Balaji Sitharaman; Tatiana Y Zakharian; Anita Saraf; Preeti Misra; Jared Ashcroft; Su Pan; Quynh P Pham; Antonios G Mikos; Lon J Wilson; David A Engler
Journal:  Mol Pharm       Date:  2008-05-28       Impact factor: 4.939

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.